Isomorphic Labs
PulseAugur coverage of Isomorphic Labs — every cluster mentioning Isomorphic Labs across labs, papers, and developer communities, ranked by signal.
- partners with Virtual Biology Initiative 95%
- founded by Jeff Dean 90%
- founded Discovery Loop 90%
- invested in Discovery Loop 90%
- spun off from Eli Lilly and Company 90%
- spun off from John Michael Jumper 90%
- invested by Thrive Capital 90%
- spun off from Novartis 90%
- founded Novartis 90%
- affiliated with Alphabet Inc. 70%
- parent of Alphabet Inc. 70%
- invested in Chan Zuckerberg Biohub 70%
- 2026-11-05 funding Isomorphic Labs is reportedly in talks to raise approximately $5 billion at a valuation near $50 billion. source
- 2026-10-07 partnership Isomorphic Labs joined the Virtual Biology Initiative as a founding member to advance AI in medicine and disease treatment. source
- 2026-09-29 product_launch Isomorphic Labs is building a new AI-driven platform to accelerate medicine discovery. source
- 2026-07-17 product_launch Isomorphic Labs launched its Drug Design Engine, a new platform for drug discovery. source
- 2026-06-11 product_launch Isomorphic Labs is developing advanced protein modeling tools to accelerate AI-driven drug discovery. source
- 2026-05-27 funding Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital to accelerate its AI drug discovery efforts. source
- 2026-05-13 funding Isomorphic Labs secured $2.1 billion in Series B funding. source
- 2026-05-12 funding Isomorphic Labs secured $2.1 billion in Series B funding.
- 2026-05-12 funding Isomorphic Labs raised $2.1 billion in a Series B funding round.
- 2026-04-24 funding Isomorphic Labs closed a $2.1 billion Series B funding round led by Thrive Capital. source
3 day(s) with sentiment data
-
Isomorphic Labs in talks for $5B funding at $50B valuation
Isomorphic Labs, a drug discovery company originating from Google DeepMind, is reportedly in discussions to secure approximately $5 billion in funding. This potential investment would place the company's valuation near …
-
Big Tech, US Gov, and Biohub invest $1.8B in AI for life sciences
A consortium including Big Tech companies, the US government, and the Chan Zuckerberg Biohub is investing $1.8 billion to advance AI's understanding of biological life. This initiative aims to leverage AI for breakthrou…
-
AI shifts focus to complex biological systems and life sciences
A significant shift is occurring in the AI landscape, moving beyond large language models and agents towards tackling complex biological systems. Initiatives like the Chan Zuckerberg Biohub's Virtual Biology program, ba…
-
Anthropic's Claude AI triggers false police report; $300M invested in virtual cell research
Anthropic's Claude AI mistakenly reported a "witnessed" event to the police after a test, leading to a two-month delay before authorities realized it was a false alarm. Separately, Google DeepMind, Meta, and Isomorphic …
-
Global consortium commits $1.8B to AI-ready biological data generation
A significant international collaboration has been launched with an $1.8 billion commitment to generate and share AI-ready biological data. This initiative, involving Biohub, the U.S. Department of Energy, and the Natio…
-
Global AI Biology Data Initiative Secures $1.8B from US Gov, Meta, Google DeepMind
A global initiative to build AI-ready biological data has secured a $1.8 billion commitment from various entities, including the US government, Meta, Google DeepMind, and Isomorphic Labs. The Virtual Biology Initiative,…
-
Zuckerberg Biohub expands AI-driven cell simulation to $1.8B
Mark Zuckerberg and Priscilla Chan's Chan Zuckerberg Biohub has expanded its Virtual Biology Initiative to $1.8 billion, aiming to use AI to simulate human cells. This effort involves significant contributions from the …
-
Isomorphic Labs joins Virtual Biology Initiative to advance AI in medicine
Isomorphic Labs has joined the Virtual Biology Initiative (VBI) as a founding member, aiming to accelerate disease understanding and treatment. CEO Demis Hassabis highlighted the initiative's focus on applying AI to med…
-
Biohub launches $1.8B initiative for human cell predictive models with tech giants
The Chan Zuckerberg Biohub has launched a five-year initiative with an $1.8 billion investment to create predictive models of the human cell. Major tech companies including Google DeepMind, Meta, and Isomorphic Labs, al…
-
Google, Meta Invest $300M in Zuckerberg's Biohub for AI Drug Discovery
Google, Meta, and Isomorphic Labs are jointly investing $300 million into Biohub, a nonprofit biomedical research organization founded by Mark Zuckerberg. This funding will support efforts to create a 'virtual cell' for…
-
Google, Meta invest $300M in Zuckerberg's AI-driven virtual cell research
Google DeepMind, Meta, and Isomorphic Labs are collectively investing $300 million into Biohub, a nonprofit biomedical research organization founded by Mark Zuckerberg and Priscilla Chan. This funding is part of a large…
-
Zuckerberg's Biohub, Google, Meta launch $1.8B AI virtual cell initiative · 4 sources tracked
The Chan Zuckerberg Biohub, backed by Mark Zuckerberg and Priscilla Chan, is spearheading a $1.8 billion initiative to develop AI models capable of predicting cell behavior. This ambitious project involves a collaborati…
-
Isomorphic Labs pioneers AI-driven drug discovery with new platform
Isomorphic Labs is developing a new AI-driven approach to drug discovery, aiming to accelerate the creation of novel medicines. The company is leveraging its proprietary AI platform, which builds upon foundational techn…
-
AI for AI: Labs Automate Model Development, Accelerating AGI Race
The concept of "AI for AI" is emerging as a core focus in the development of next-generation large language models. This approach leverages AI's capabilities to automate and accelerate the research and development proce…
-
ByteDance spin-off Anew Labs raises $290M for AI drug discovery
Anew Labs, a former unit of ByteDance, has secured US$290 million in funding at a US$1.5 billion valuation. The Shanghai-based AI drug discovery firm's funding round was backed by prominent venture capital firms includi…
-
Google DeepMind releases AI-powered AlphaGenome Atlas for 9 billion DNA variants · 9 sources tracked
Google DeepMind has launched the AlphaGenome Atlas, a comprehensive database that uses AI to predict the molecular effects of approximately 9 billion possible single-nucleotide variants in the human genome. This resourc…
-
AI giants pivot to health care to boost image and investor confidence · 1 source tracked
Major AI companies are increasingly focusing on health care applications to improve their public image and secure investor confidence. This strategic shift aims to counter negative perceptions surrounding AI's environme…
-
AI in Drug Discovery: Algorithms vs. Full Pipeline Value
Two recent AI-driven pharmaceutical developments, one from Anthropic and another from Moderna, have generated significant public interest. Anthropic utilized its Claude model to autonomously design protein binders for 1…
-
US patent law struggles to credit AI inventors in drug discovery
Intellectual property law currently faces a significant challenge as artificial intelligence systems are increasingly capable of generating novel drug designs. Despite AI's role in these discoveries, current patent laws…
-
Startup Vivodyne claims AI drug discovery needs better human data
A biotech startup named Vivodyne claims that the current AI drug-discovery field is hampered by a lack of high-quality, human-centric data. Vivodyne has developed modular robotic labs, called HIVE, capable of generating…